Nöroinflamasyon, sinaptik disfonksiyon ve Parkinson hastalığında [<sup>18</sup>F]DOPA-PET'in CSF belirteçleri.

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

IntroductionNeuromelanin containing cell loss, neuroinflammation and synaptic dysfunction are believed to contribute to Parkinson's disease (PD) pathogenesis. [18F]DOPA PET reflects dopamine storage capacity in the putamen, while midbrain off-target retention of [18F]RO948 is hypothesized to reflect neuromelanin.ObjectivesTo investigate associations between disease duration, cerebrospinal fluid (CSF) markers of neurodegeneration, synaptic dysfunction, neuroinflammation, and dopamine synaptic loss as measured by [18F]DOPA PET in PD patients. We further aimed to explore whether reduced midbrain retention of [18F]RO948 relates to [18F]DOPA PET and CSF markers.MethodsParticipants were part of the BioFINDER studies. CSF biomarkers were analyzed for controls (n = 623), PD participants (n = 226) and Dementia with Lewy bodies (DLB; n = 33). [18F]RO948 PET was performed in controls (n = 514), PD (n = 77) and DLB (n = 47) and [18F]DOPA PET in PD (n = 58) and DLB (n = 22).ResultsPD patients showed higher CSF neurofilament light (NfL) levels (pg/ml [mean ± SD] 159 ± 139) vs. controls (137 ± 90, p 18F]DOPA uptake correlated with longer disease duration (ρ = -0.46, p 18F]DOPA PET. Substantia nigra [18F]RO948 signal was lower in PD ([mean ± SD] 1.67 ± 0.22) vs controls (1.76 ± 0.3, p 18F]DOPA-PET.ConclusionsIn PD patients, a decrease in [18F]DOPA PET retention correlated with disease duration as well as CSF neurodegenerative and synaptic biomarkers but not with inflammatory biomarkers or [18F]RO948 PET midbrain off-target retention.

İlgili konular